WebBiohaven (NYSE:BHVN) said it acquired global rights, excluding China regions, for BHV-8000 to treat brain disorders from Hangzhou Highlightll Pharmaceutical. Highlightll will get $10M cash upfront ... WebMar 23, 2024 · Biohaven (BHVN Quick QuoteBHVN- Free Report) announced that it has acquired global license rights (excluding China regions) for BHV-8000 from Hangzhou Highlightll Pharmaceuticals for...
THE 15 BEST Things to Do in Hangzhou - Tripadvisor
WebMar 22, 2024 · BHV-8000 was licensed from Hangzhou Highlightll Pharmaceutical Co. Ltd. Biohaven anticipates advancing the agent into a phase 1 study in 2024. Highlightll will … WebNov 24, 2024 · Brief Summary: This is a randomized, double-blind, double-dummy, tofacitinib-parallel-group, phase 2A study to assess the safety and efficacy of TLL-018 in … hyperion non skyblock
BioCentury - Hangzhou Highlightll: Twice the target, hold the tox
WebMar 22, 2024 · Biohaven ( NYSE: BHVN) said it acquired global rights, excluding China regions, for BHV-8000 to treat brain disorders from Hangzhou Highlightll Pharmaceutical. Highlightll will get $10M cash... WebMar 22, 2024 · Biohaven ( BHVN) was up more than 2% after saying it has acquired a license from Hangzhou Highlightll Pharmaceutical to develop BHV-8000, a treatment candidate for immune-mediated brain disorders. WebNov 24, 2024 · Hangzhou Highlightll Pharmaceutical Co., Ltd . Information provided by (Responsible Party): Hangzhou Highlightll Pharmaceutical Co., Ltd. Study Details; Tabular View; No Results Posted; Disclaimer; How to Read a Study Record; No Study Results Posted on ClinicalTrials.gov for this Study hyperion nms